Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Corporate Law Client Strategies in Asia

Related Content

Developments in W&I Insurance in Asia

Draft Implementing Rules of China’s Human Genetic Resources Regulations as Applied to Foreign Persons

Chinese Cross Border Life Sciences Strategic Transactions in the Age of COVID-19

Hong Kong to Revamp Limited Partnership Regime to Attract Private Funds

Hong Kong Celebrates Ten Years

Video: Goodwin in Asia

Release of Names With Interests in Offshore Entities: Ramifications

Chambers Global 2024 Recognizes Goodwin Lawyers and Practices as Worldwide Leaders

Asia Secondaries – Five Themes for ’25 (SecondaryLink)

Biotheus Enters Into Strategic Partnership with BioNTech

International Law Firms Double Down on Singapore Expansion (International Financial Law Review)

Chambers Global 2023 Recognizes Goodwin Lawyers and Practices as Worldwide Leaders

LionRock Capital Closes Sale of Clarks Investment to Viva China

Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies

China’s Kelun Pharma Jumps on Licensing New Cancer Drug to Merck